KR101086254B1 - 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법 - Google Patents

생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법 Download PDF

Info

Publication number
KR101086254B1
KR101086254B1 KR1020040089455A KR20040089455A KR101086254B1 KR 101086254 B1 KR101086254 B1 KR 101086254B1 KR 1020040089455 A KR1020040089455 A KR 1020040089455A KR 20040089455 A KR20040089455 A KR 20040089455A KR 101086254 B1 KR101086254 B1 KR 101086254B1
Authority
KR
South Korea
Prior art keywords
solid dispersion
franlukast
bioavailability
composition
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020040089455A
Other languages
English (en)
Korean (ko)
Other versions
KR20060040211A (ko
Inventor
오준교
오용호
신호철
정지선
엄기안
민동선
이남규
이주영
임광진
김태곤
김정태
장우제
신동철
김웅식
Original Assignee
에스케이케미칼주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36319405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101086254(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에스케이케미칼주식회사 filed Critical 에스케이케미칼주식회사
Priority to KR1020040089455A priority Critical patent/KR101086254B1/ko
Priority to PCT/KR2005/003686 priority patent/WO2006049433A1/en
Priority to ARP050104618A priority patent/AR051758A1/es
Priority to JP2007540251A priority patent/JP5232472B2/ja
Priority to MX2007005427A priority patent/MX2007005427A/es
Priority to TW094138786A priority patent/TWI380829B/zh
Publication of KR20060040211A publication Critical patent/KR20060040211A/ko
Publication of KR101086254B1 publication Critical patent/KR101086254B1/ko
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020040089455A 2004-11-04 2004-11-04 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법 Expired - Lifetime KR101086254B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020040089455A KR101086254B1 (ko) 2004-11-04 2004-11-04 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
MX2007005427A MX2007005427A (es) 2004-11-04 2005-11-03 Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida.
ARP050104618A AR051758A1 (es) 2004-11-04 2005-11-03 Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida
JP2007540251A JP5232472B2 (ja) 2004-11-04 2005-11-03 向上された生体利用効率を備えるプランルカスト固体分散体組成物およびその固体分散体の製造方法
PCT/KR2005/003686 WO2006049433A1 (en) 2004-11-04 2005-11-03 Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion
TW094138786A TWI380829B (zh) 2004-11-04 2005-11-04 具有改良的生物可利用率之普侖斯特（ｐｒａｎｌｕｋａｓｔ）固態分散物組成物及製備該固態分散物之方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040089455A KR101086254B1 (ko) 2004-11-04 2004-11-04 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법

Publications (2)

Publication Number Publication Date
KR20060040211A KR20060040211A (ko) 2006-05-10
KR101086254B1 true KR101086254B1 (ko) 2011-11-24

Family

ID=36319405

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020040089455A Expired - Lifetime KR101086254B1 (ko) 2004-11-04 2004-11-04 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법

Country Status (6)

Country Link
JP (1) JP5232472B2 (enExample)
KR (1) KR101086254B1 (enExample)
AR (1) AR051758A1 (enExample)
MX (1) MX2007005427A (enExample)
TW (1) TWI380829B (enExample)
WO (1) WO2006049433A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101446129B1 (ko) * 2012-10-10 2014-10-06 조선대학교산학협력단 프란루카스트-함유 고형 제제의 제조방법
KR20160141620A (ko) 2015-06-01 2016-12-09 삼아제약 주식회사 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법
KR20240164596A (ko) 2023-05-09 2024-11-20 삼아제약 주식회사 복약편의성이 증진된 프란루카스트 함유 약제학적 조성물
KR20250015905A (ko) 2023-07-18 2025-02-03 삼아제약 주식회사 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물
KR20250052834A (ko) 2023-10-12 2025-04-21 주식회사 다산제약 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101233235B1 (ko) * 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
EP4008314A3 (en) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Thermo-kinetic mixing for pharmaceutical applications
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
KR101381881B1 (ko) * 2012-03-12 2014-04-04 충남대학교산학협력단 용해도 및 용출율이 개선된 프란루카스트 나노 고체 분산체의 제조방법
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
CA3099901C (en) 2018-07-13 2024-03-19 Council Of Scientific & Industrial Research Solid dispersion comprising an anticancer compound for improved solubility and efficacy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089574A1 (en) * 2000-05-20 2001-11-29 Sang Deuk Lee Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
US20030215496A1 (en) 1999-11-23 2003-11-20 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040058896A1 (en) 2000-12-07 2004-03-25 Rango Dietrich Pharmaceutical preparation comprising an active dispersed on a matrix

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
DE69625813T2 (de) * 1995-06-12 2003-09-04 Ono Pharmaceutical Co. Ltd., Osaka Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
US5858509A (en) * 1996-11-15 1999-01-12 Digital Equipment Corporation Attenuating vibrations in a mounting shelf for multiple disk drives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215496A1 (en) 1999-11-23 2003-11-20 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001089574A1 (en) * 2000-05-20 2001-11-29 Sang Deuk Lee Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
US20040058896A1 (en) 2000-12-07 2004-03-25 Rango Dietrich Pharmaceutical preparation comprising an active dispersed on a matrix

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101446129B1 (ko) * 2012-10-10 2014-10-06 조선대학교산학협력단 프란루카스트-함유 고형 제제의 제조방법
KR20160141620A (ko) 2015-06-01 2016-12-09 삼아제약 주식회사 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법
KR20240164596A (ko) 2023-05-09 2024-11-20 삼아제약 주식회사 복약편의성이 증진된 프란루카스트 함유 약제학적 조성물
KR20250015905A (ko) 2023-07-18 2025-02-03 삼아제약 주식회사 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물
KR20250052834A (ko) 2023-10-12 2025-04-21 주식회사 다산제약 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법

Also Published As

Publication number Publication date
WO2006049433A1 (en) 2006-05-11
TW200621307A (en) 2006-07-01
JP5232472B2 (ja) 2013-07-10
AR051758A1 (es) 2007-02-07
KR20060040211A (ko) 2006-05-10
JP2008519067A (ja) 2008-06-05
MX2007005427A (es) 2012-10-02
TWI380829B (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
KR101159617B1 (ko) 구강내 속붕해성 정제
KR100479521B1 (ko) Ｎ-피페리디노-3-피라졸카르복사미드 유도체, 그것의 염 및 그것들의 용매화물의 경구 투여용 약제학적 조성물
US6455053B1 (en) Quickly soluble solid preparations
KR101086254B1 (ko) 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
KR100381834B1 (ko) 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
EP2886109B1 (en) Medicament-containing hollow particle
KR20090042961A (ko) 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
CA1146545A (en) Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin
KR100908418B1 (ko) 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법
JP2004131393A (ja) 易溶出性製剤
EP1652524A1 (en) Dry syrup containing loratadine
EP3834821B1 (en) Dropping pill comprising ginkgo terpene lactones as active components and preparation method therefor
KR0172134B1 (ko) 고형 제제
CN114699384A (zh) 一种药物掩味方法、药物及其应用
KR20040072682A (ko) 삼환성 트리아졸로벤자제핀 유도체의 비결정 물질
JPH11116465A (ja) 迅速溶解性製剤およびその製造法
KR102760108B1 (ko) 수용해도와 투과도를 향상시켜 생체이용률이 개선된 무정형 아픽사반 고체분산체 제제 및 그의 서방성 정제
KR100671714B1 (ko) 미분화된 펠로디핀 함유 지속 방출성 제제
JP2813792B2 (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
KR20130025851A (ko) 메게스트롤 속붕해정 및 이의 제조 방법
CN101658543A (zh) 千层塔片及其制造方法
CN101658544A (zh) 千层塔控释片及其制造方法
CN101623317A (zh) 千层塔口崩片及其制造方法
HK1027504A (en) Quickly soluble solid preparations
CN101785762A (zh) 石杉碱甲口崩片及其制造方法

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20041104

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091028

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20041104

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110519

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20111031

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20111117

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20111118

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20141020

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20141020

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20151020

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20151020

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20161020

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20161020

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20171020

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20171020

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20181101

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20181101

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20191104

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20191104

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20201026

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20211026

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20221020

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20250504

Termination category: Expiration of duration